| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CART |
| Uniprot No | Q16568 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-116aa |
| 氨基酸序列 | MESSRVRLLP LLGAALLLML PLLGTRAQED AELQPRALDI YSAVDDASHE KELIEALQEV LKKLKSKRVP IYEKKYGQVP MCDAGEQCAV RKGARIGKLC DCPRGTSCNS FLLKCL |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CAR-T重组蛋白技术的参考文献及其摘要概述：
---
1. **文献名称**：*Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia*
**作者**：June, C.H. et al.
**摘要**：该研究报道了靶向CD19的CAR-T细胞在难治性白血病中的临床效果，通过重组蛋白技术构建的CAR分子成功引导T细胞清除肿瘤细胞，证实了重组受体设计的治疗潜力。
---
2. **文献名称**：*Design of Chimeric Antigen Receptors with Integrated Critical Signaling Domains*
**作者**：Sadelain, M. et al.
**摘要**：文章系统分析了CAR结构中不同信号域(如CD28、4-1BB)对T细胞功能的影响，提出了基于重组蛋白优化CAR结构的策略，以增强抗肿瘤活性和持久性。
---
3. **文献名称**：*Recombinant Antibody-Based CARs: Improving Targeting Specificity and Safety*
**作者**：Hudecek, M. et al.
**摘要**：探讨了利用重组单链抗体(scFv)技术设计CAR的抗原识别域，通过重组蛋白工程减少脱靶毒性，提升CAR-T细胞治疗的安全性。
---
注：以上文献为示例，实际引用时需核对具体论文信息。如需近期研究，可补充2020年后文献，如涉及CAR-T与重组蛋白分泌调控等方向。
**Background of CAR-T Recombinant Proteins**
Chimeric antigen receptor (CAR) recombinant proteins are engineered molecules central to CAR-T cell therapy, a groundbreaking approach in immunotherapy. CARs are synthetic receptors designed to redirect T cells to recognize and eliminate specific cancer cells. Structurally, a CAR recombinant protein typically comprises three key domains: an extracellular antigen-binding domain (often derived from single-chain variable fragments of antibodies), a transmembrane domain for stability, and an intracellular signaling domain (e.g., CD3ζ) combined with costimulatory motifs (e.g., CD28. 4-1BB) to enhance T cell activation and persistence.
The development of CAR-T technology emerged from decades of research in immunology and genetic engineering. Early CAR designs (first-generation) lacked costimulatory signals, limiting efficacy. Subsequent generations incorporated additional signaling domains, improving T cell proliferation, cytotoxicity, and durability. Recombinant protein engineering enables precise customization of CAR constructs, optimizing antigen specificity, binding affinity, and signaling intensity to balance therapeutic potency with safety.
CAR-T therapies gained prominence for treating hematologic malignancies, notably CD19-targeted CAR-T cells for B-cell leukemias and lymphomas. However, challenges persist in solid tumors due to heterogeneous antigen expression, immunosuppressive microenvironments, and on-target/off-tumor toxicity. Innovations in CAR recombinant proteins now explore modular designs, safety switches (e.g., suicide genes), and multi-targeting strategies to address these limitations.
Manufacturing CAR-T cells relies on viral or non-viral delivery of CAR recombinant protein-encoding genes into patient-derived T cells. Quality control of recombinant proteins ensures consistency in CAR expression and function, critical for clinical outcomes.
Despite transformative clinical success, CAR-T therapy faces hurdles in cost, accessibility, and toxicity management. Ongoing research focuses on universal CAR-T platforms, in vivo delivery systems, and next-generation CAR designs to broaden applicability. CAR recombinant proteins remain pivotal in advancing adoptive cell therapies, exemplifying the synergy between molecular biology and translational medicine.
×
